Celltrion agrees with Nippon Kayaku for rituximab biosimilar in Japan

April 28, 2017 11:04 AM

celltrion-rituximab-truxima-biosimilarnews

Celltrion Healthcare, said on April 27 it has named Nippon Kayaku as its Japanese retail partner for Truxima, The Investor reports. The Japanese drug company has secured the exclusive sales rights for Celltrion’s three biosimilar drugs — Truxima, Remsima and Herzuma.

The two companies will seek Japanese regulatory approval for Truxima after collecting patient data through clinical studies in the country. Truxima is a biosimilar version of Roche’s blockbuster lymphatic cancer treatment Rituxan/Mabthera.

“Through the partnership with Celltrion, Nippon Kayaku will establish a strong foothold in the fast-growing biosimilar market in Japan,” the Tokyo-headquartered firm said in a statement.

Rituxan, also known as Mabthera, is Roche’s top-selling drug that generated revenue of US$7.35 billion last year. Japan makes up nearly 5 percent of the global sales.

Celltrion launched Remsima, the biosimilar version of Johnson & Johnson’s Remicade, in Japan in 2014. In April this year, the company also filed for approval to sell Herzuma, referencing Roche’s Herceptin, in the country.

“We will carry out aggressive marketing activities for Truxima and promote awareness of biosimilar drugs overall along with Nippon Kayaku,” Celltrion said in a statement.

Celltrion started selling Truxima in the UK since April before its Korean launch set for June this year.

Source: The Investor

 

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!